PMID- 29869645
OWN - NLM
STAT- MEDLINE
DCOM- 20180730
LR  - 20211204
IS  - 1699-3993 (Print)
IS  - 1699-3993 (Linking)
VI  - 54
IP  - 4
DP  - 2018 Apr
TI  - Daclatasvir, asunaprevir and beclabuvir fixed-dose combination for patients with 
      genotype 1 chronic hepatitis C.
PG  - 237-244
LID - 10.1358/dot.2018.54.4.2795154 [doi]
AB  - Hepatitis C is killing 350,000 persons per year worldwide, 60% of the cases being 
      patients with genotype 1 (GT-1). The fixed-dose tablet combination of daclatasvir 
      (30 mg)/asunaprevir (200 mg)/beclabuvir (75 mg), DCV-TRIO, is one of the latest 
      drugs in the pipeline of interferon-free direct-acting antiviral hepatitis C 
      virus (HCV) therapies. DCV-TRIO increases the genetic barrier to resistance by 
      acting at the same time against three hepatitis C key viral proteins. Results 
      from the UNITY 1, 2, 3 and 4 phase III clinical trials showed that DCV-TRIO 
      exhibited high sustained virologic responses at 12 weeks (between 92% and 100% 
      for HCV GT-1 treatment-naive patients). Furthermore, DCV-TRIO was well tolerated 
      in all studies with reported adverse events (AEs) with an incidence of at least 
      10% mostly being headache, diarrhea, fatigue and nausea and few AE-related 
      discontinuations. Further research should focus on more real-life data on 
      DCV-TRIO and on developing a pill regimen that works on other HCV genotypes with 
      high genetic barriers and that is available at a reduced cost.
CI  - Copyright 2018 Clarivate Analytics.
FAU - Thiam, A
AU  - Thiam A
AD  - Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada. 
      Astou.thiam@vidc.ca.
FAU - Conway, B
AU  - Conway B
AD  - Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Spain
TA  - Drugs Today (Barc)
JT  - Drugs of today (Barcelona, Spain : 1998)
JID - 101160518
RN  - 0 
      (8-cyclohexyl-N-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamide)
RN  - 0 (Antiviral Agents)
RN  - 0 (Benzazepines)
RN  - 0 (Carbamates)
RN  - 0 (Drug Combinations)
RN  - 0 (Imidazoles)
RN  - 0 (Indoles)
RN  - 0 (Isoquinolines)
RN  - 0 (Pyrrolidines)
RN  - 0 (Sulfonamides)
RN  - HG18B9YRS7 (Valine)
RN  - LI2427F9CI (daclatasvir)
RN  - S9X0KRJ00S (asunaprevir)
SB  - IM
MH  - Antiviral Agents/*administration & dosage/adverse effects
MH  - Benzazepines/*administration & dosage/adverse effects
MH  - Carbamates
MH  - Drug Combinations
MH  - Drug Resistance, Viral/genetics
MH  - Genotype
MH  - Hepacivirus/*drug effects/genetics/pathogenicity
MH  - Hepatitis C, Chronic/diagnosis/*drug therapy/virology
MH  - Humans
MH  - Imidazoles/*administration & dosage/adverse effects
MH  - Indoles/*administration & dosage/adverse effects
MH  - Isoquinolines/*administration & dosage/adverse effects
MH  - Pyrrolidines
MH  - Sulfonamides/*administration & dosage/adverse effects
MH  - Sustained Virologic Response
MH  - Treatment Outcome
MH  - Valine/analogs & derivatives
OTO - NOTNLM
OT  - Direct-acting antivirals
OT  - Inhibitors of NS5A, NS3 and NS5B
OT  - Asunaprevir
OT  - Beclabuvir
OT  - Daclatasvir
OT  - Fixed-dose combination
OT  - HCV therapy
EDAT- 2018/06/06 06:00
MHDA- 2018/07/31 06:00
CRDT- 2018/06/06 06:00
PHST- 2018/06/06 06:00 [entrez]
PHST- 2018/06/06 06:00 [pubmed]
PHST- 2018/07/31 06:00 [medline]
AID - 2795154 [pii]
AID - 10.1358/dot.2018.54.4.2795154 [doi]
PST - ppublish
SO  - Drugs Today (Barc). 2018 Apr;54(4):237-244. doi: 10.1358/dot.2018.54.4.2795154.